Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Drug Discov Today ; 29(5): 103967, 2024 May.
Article in English | MEDLINE | ID: mdl-38555033

ABSTRACT

Single-domain antibodies (sdAbs) hold promise for developing new biopharmaceuticals to treat neglected tropical diseases (NTDs), including snakebites, which are severe and occur frequently. In addition, limitations of conventional snakebite treatments, especially in terms of local action, and the global antivenom crisis incentivize the use of this biotechnological tool to design next-generation snakebite antivenoms. Conventional antivenoms for snakebite treatment are usually composed of immunoglobulin G or F(ab')2 fragments derived from the plasma of immunized animals. sdAbs, the smallest antigen-binding fragments, are derived from the variable domains of camelid heavy-chain antibodies. sdAbs may have some advantages over conventional antivenoms for local toxicity, such as better penetration into tissues due to their small size, and high solubility and affinity for venom antigens due to their unique antigen-binding loops and ability to access cryptic epitopes. We present an overview of current antivenom therapy in the context of sdAb development for toxin neutralization. Furthermore, strategies are presented for identifying snake venom's major toxins as well as for developing antisnake toxin sdAbs by employing proteomic tools for toxin neutralization.


Subject(s)
Antivenins , Proteomics , Single-Domain Antibodies , Snake Bites , Snake Venoms , Antivenins/immunology , Animals , Snake Bites/drug therapy , Snake Bites/immunology , Single-Domain Antibodies/immunology , Single-Domain Antibodies/pharmacology , Humans , Snake Venoms/immunology , Proteomics/methods
2.
Parasite Immunol ; 43(3): e12805, 2021 03.
Article in English | MEDLINE | ID: mdl-33131089

ABSTRACT

Leishmania braziliensis is the main causative agent of American tegumentary leishmaniasis in Brazil. Current treatment includes different drugs that have important side effects and identification of cases of parasite resistance to treatment support the search for new therapeutic strategies. Recent findings have indicated that CXCL10, a chemokine that recruits and activates Th1 cells, NK cells, macrophages, dendritic cells and B lymphocytes, is a potential alternative to treat Leishmania infection. Here, we tested CXCL10 immunotherapy against experimental infection caused by an antimony-resistant isolate of Leishmania braziliensis. Following infection, mice were treated with CXCL10 for 7 days after onset of lesions. We demonstrate that mice treated with CXCL10 controlled lesion progression and parasite burden more efficiently comparing to controls. An increased IFN-γ, IL-10, TGF-ß and low IL-4 production combined with a distinct inflammatory infiltrate composed by activated macrophages, lymphocytes and granulomas was observed in the CXCL10-treated group comparing to controls. However, CXCL10 and Glucantime combined therapy did not improve CXCL10-induced protective effect. Our findings reinforce the potential of CXCL10 immunotherapy as an alternative treatment against infection caused by L. braziliensis resistant to conventional chemotherapy.


Subject(s)
Chemokine CXCL10/therapeutic use , Immunologic Factors/therapeutic use , Leishmania braziliensis/drug effects , Leishmaniasis, Cutaneous/drug therapy , Leishmaniasis, Cutaneous/parasitology , Animals , Antimony/pharmacology , Brazil , Female , Interleukin-10/immunology , Leishmania braziliensis/immunology , Leishmania braziliensis/isolation & purification , Leishmaniasis, Cutaneous/immunology , Macrophages/immunology , Male , Mice , Mice, Inbred BALB C , Nitric Oxide/pharmacology , Th1 Cells/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...